CEO Salary & Executive Compensation
Bristol-Myers Squibb BMY
CEO: Chris Boerner · Pharmaceuticals · 34,300 employees
Chris Boerner, CEO of Bristol-Myers Squibb (BMY), earned $12.0M in total compensation in 2025. Bristol-Myers Squibb receives a Pay-for-Performance grade of C (64/100), with a CEO-to-worker pay ratio of 120:1 and a say-on-pay shareholder approval of 86.7%. The company's 3-year total shareholder return is +3.3%.
How Bristol-Myers Squibb CEO Pay Compares
Chris Boerner's $12.0M total compensation is 0% below the Pharmaceuticals industry median of $12.0M. The 120:1 CEO-to-worker pay ratio is 4% lower than the industry average of 125:1.
Chris Boerner, CEO of Bristol-Myers Squibb (BMY), received $12.0M in total reported compensation. The package mix typical at this scale: a small base salary, a larger stock-award component, and performance-tied incentives that vest over multiple years based on relative TSR or earnings benchmarks.
The CEO-to-median-worker pay ratio runs 120x. Lower ratios typically reflect companies with higher-paid workforces (financial services, technology, professional services) where the median worker pay denominator is itself substantial. Three-year performance has been roughly flat — TSR of 3.3% alongside 3.5% revenue growth. Flat performance over a multi-year window is where pay-versus-performance debates get the most heated: large compensation packages without commensurate shareholder returns are the modal complaint at annual meetings.
Shareholders supported the compensation package at 87% on the most recent say-on-pay vote. Solid support without overwhelming endorsement is the typical pattern for established public companies with conventional compensation programs. Bristol-Myers Squibb operates in Pharmaceuticals with 34,300 employees and $45.0B in annual revenue, and currently carries a market capitalization of $100.0B. Pay comparisons across companies require controlling for these structural factors — a $20M package at a $10B-revenue tech company reads differently than the same package at a $1B-revenue industrial.
Source: SEC EDGAR — DEF 14A proxy statements for Bristol-Myers Squibb (BMY).
Compensation Breakdown
Chris Boerner's $12.0M total compensation package for fiscal year 2025 includes $1.2M in base salary, $6.0M in stock awards, $1.4M in option awards, and $1.8M in bonus and non-equity incentives.
Compensation History
| Year | Salary | Bonus | Stock Awards | Options | Non-Equity | Other | Total |
|---|---|---|---|---|---|---|---|
| 2025 | $1.2M | - | $6.0M | $1.4M | $1.8M | $1.3M | $12.0M |
| 2024 | $1.2M | - | $6.0M | $1.4M | $1.8M | $1.3M | $12.0M |
| 2023 | $1.2M | - | $6.0M | $1.4M | $1.8M | $1.3M | $12.0M |
| 2022 | $1.2M | - | $6.0M | $1.4M | $1.8M | $1.3M | $12.0M |
All compensation data is sourced from SEC DEF 14A proxy filings submitted to EDGAR. The Economic Policy Institute's CEO pay analysis provides additional context on executive compensation trends across industries.
Named Executive Officers
Peer CEO Compensation
Chris Boerner, CEO of Bristol-Myers Squibb (BMY), earns $12.0M in total compensation. This includes base salary, stock awards, option awards, and other incentives as reported in the company's most recent DEF 14A proxy statement.
Frequently Asked Questions
Chris Boerner, CEO of Bristol-Myers Squibb (BMY), earns $12.0M in total compensation. This includes base salary, stock awards, option awards, and other incentives as reported in the company's most recent DEF 14A proxy statement.
Bristol-Myers Squibb has a Pay-for-Performance Score of C (64/100). The company's 3-year total shareholder return is +3.3%, and the say-on-pay shareholder vote passed with 86.7% approval.
The CEO-to-median-worker pay ratio at Bristol-Myers Squibb is 120:1. The median worker at Bristol-Myers Squibb earns $100K per year, while CEO Chris Boerner earns $12.0M in total compensation.
Bristol-Myers Squibb employs approximately 34,300 people. The company operates in the Pharmaceuticals industry within the Healthcare sector, generating $45.0B in annual revenue.